Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,164.12 -15.56 (-0.19%) Bitcoin USD
60,857.38 -637.75 (-1.04%) CMC Crypto 200
1,268.35 -15.48 (-1.21%)
AMRX Sep 2024 2.500 call
| Previous close | 4.5000 |
| Open | 4.5000 |
| Bid | 2.2500 |
| Ask | 4.6000 |
| Strike | 2.50 |
| Expiry date | 2024-09-20 |
| Day's range | 4.5000 - 4.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
Business WireAmneal Releases 2023 Environmental, Social and Governance Report
BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit
Business WireAmneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
BRIDGEWATER, N.J., June 05, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40.
Business WireAmneal to Participate at Upcoming Investor Conference
BRIDGEWATER, N.J., May 22, 2024--Amneal to Participate at Upcoming Investor Conference
